Ibrahim Elgabry, MD
Cardiovascular Disease · Woonsocket, RINPI 1518969195
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,215 of the $71,542 with a category attached, or 84.2%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 65.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $23,515 and has fallen 81.7% since, to $4,309 in 2025. Among cardiovascular disease clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $244.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$46K
- E.r. Squibb & Sons, L.L.C.$14K
- Pfizer$5K
- Scpharmaceuticals Inc.$3K
- Medtronic$1K
- Johnson & Johnson$692
- plus $1K from 19 others
What the payments were for
- Consulting fees$1,4502%
- Speaking & faculty fees$60,21584%
- Travel & lodging$1,8843%
- Food & beverage$7,99311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 78 | $46,497 |
| E.r. Squibb & Sons, L.L.C. | 41 | $13,905 |
| Pfizer | 49 | $5,163 |
| Scpharmaceuticals Inc. | 4 | $2,561 |
| Medtronic(2 entities) | 23 | $1,444 |
| Johnson & Johnson | 36 | $692 |
| Novartis | 25 | $397 |
| Shockwave Medical, Inc | 5 | $127 |
| Abbott | 2 | $118 |
| Amarin Pharma, Inc. | 5 | $90 |
| Boehringer Ingelheim | 4 | $89 |
| Boston Scientific | 3 | $66 |
| Actelion Pharmaceuticals US, Inc. | 2 | $53 |
| Baxter Healthcare | 2 | $53 |
| Gilead | 2 | $44 |
| AstraZeneca | 2 | $37 |
| Amgen | 2 | $33 |
| Heartflow, Inc. | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Cook Medical LLC | 1 | $23 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| GE HealthCare | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$44,293
- ELIQUIS$16,407
- FUROSCIX$2,525
- Azure$465
- Reveal LINQ$180
- Abre$178
- ClosureFast$107
How this compares
$71,542 in reported general payments places this provider in the 95th percentile of 86 cardiovascular disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,161 | $744,060 |
| EntrestoSacubitril/Valsartan | 290 | $211,672 |
| JardianceEmpagliflozin | 190 | $132,335 |
| FarxigaDapagliflozin Propanediol | 169 | $103,878 |
| XareltoRivaroxaban | 74 | $62,490 |
| Ranolazine ErRanolazine | 285 | $30,069 |
| BrilintaTicagrelor | 44 | $22,318 |
| Dofetilide | 105 | $20,040 |
| Atorvastatin Calcium | 1,127 | $12,601 |
| Repatha SureclickEvolocumab | 11 | $10,109 |
| CorlanorIvabradine Hcl | 13 | $9,461 |
| Carvedilol | 615 | $8,550 |
| Ezetimibe | 387 | $8,414 |
| Metoprolol Succinate | 574 | $6,990 |
| Bumetanide | 171 | $5,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,163 | $744,0601,161 claims |
| NovartisEntresto | $397 | $211,672290 claims |
| Boehringer IngelheimJardiance | $89 | $132,335190 claims |
| AstraZenecaFarxiga, Brilinta | $37 | $126,196213 claims |
| Johnson & JohnsonXarelto | $692 | $62,49074 claims |
| AmgenCorlanor | $33 | $9,46113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 86 cardiovascular disease providers in Rhode Island.
Other cardiovascular disease in Woonsocket
- George BourganosWoonsocket$16K
- Hani SabbourWoonsocket$2K
- Anila Peter-FahertyWoonsocket$1K
- Harold MooreWoonsocket$928
- Thomas LannaWoonsocket$562
- Kirit DesaiWoonsocket$447
- Neal KelleyWoonsocket$364
- Florian KociWoonsocket$296
- Richard RegnanteWoonsocket$234
- Cynthia AlvesWoonsocket$218
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.